Every material Form 8-K Elanco filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Elanco Animal Health Inc reported third quarter 2026 revenue of $1.265 billion, representing an 11% increase year-over-year, and net income of $18 million. Driven by strong demand and gross margin expansion, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted earnings per share.
Third quarter revenue reached $1.265 billion, up 11% reported and 9% organic constant currency.
Reported net income was $18 million, while adjusted EPS was $0.27.
Full year 2026 revenue guidance was raised to $5.155 billion to $5.18 billion.
Net leverage ratio improved to 2.9x Adjusted EBITDA at the end of the third quarter.
Elanco reported second quarter 2026 revenue of $1.37 billion, up 10% from a year earlier, and reported net income of $54 million, or $0.11 per diluted share, compared with $11 million a year earlier. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA and adjusted EPS, and also gave third-quarter guidance. Shareholders get higher expected full-year results, though the third-quarter revenue and EPS ranges are lower than the second quarter's reported figures.
Q2 2026 revenue of $1,368 million, up 10% reported and 8% organic constant currency; adjusted EPS of $0.34, up 31%
Full-year 2026 guidance raised: revenue $5.09 billion to $5.14 billion, adjusted EBITDA $1.01 billion to $1.035 billion, adjusted EPS $1.10 to $1.16
Third-quarter 2026 guidance: revenue $1,195 million to $1,220 million, adjusted EBITDA $200 million to $215 million, adjusted EPS $0.19 to $0.22
Year-end net leverage ratio target improved to approximately 3.0x adjusted EBITDA; the June 30 ratio was 3.1x
Elanco reported first-quarter 2026 revenue of $1,371 million, up 15% from a year earlier, and adjusted EPS of $0.40, up 8%. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA and adjusted EPS, which matters to shareholders because it signals stronger expected results for the year, though reported net income fell 15% to $57 million.
Q1 2026 revenue was $1,371 million, up 15% reported and 10% organic constant currency; reported net income was $57 million, down from $67 million
Full-year 2026 revenue guidance raised to $5,010 million to $5,085 million from $4,950 million to $5,020 million
Full-year adjusted EBITDA guidance raised to $975 million to $1,005 million; adjusted EPS guidance raised to $1.03 to $1.09 from $1.00 to $1.06
Second-quarter 2026 guidance: revenue of $1,300 million to $1,325 million and adjusted EPS of $0.25 to $0.28
Elanco reported fourth-quarter 2025 revenue of $1,144 million, up 12%, and a reported net loss of $276 million, which included $202 million of asset impairment, restructuring and other special charges. For full year 2025, revenue rose 6% to $4,715 million, but the company posted a reported net loss of $232 million, compared with net income of $338 million in 2024; adjusted EPS rose to $0.94 from $0.91. The company also guided 2026 revenue to $4,950 million to $5,020 million and adjusted EPS to $1.00 to $1.06.
Q4 2025 revenue $1,144 million, up 12% reported and 9% organic constant currency; adjusted EPS $0.13 vs. $0.14 a year earlier
Full year 2025 reported EPS $(0.47) vs. $0.68 in 2024; adjusted EPS $0.94 vs. $0.91
2026 guidance: revenue $4,950 million to $5,020 million; adjusted EBITDA $955 million to $985 million; adjusted EPS $1.00 to $1.06
2026 innovation revenue target raised to $1.15 billion; net leverage ratio ended 2025 at 3.6x
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Elanco filing is on SEC EDGAR ↗. 8-K briefs of other companies →